Factors affecting the choice of budesonide in the therapy of croup, asthma and chronic obstructive pulmonary disease

Magdalena Olszanecka-Glinianowicz1, Jerzy Chudek2, Anna Urcus1, Agnieszka Almgren-Rachtan4

1Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Katowice, Poland
2Department of Internal Medicine and Oncological Chemotherapy, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
3Adamed Pharma, Poland
4Pharmacovigilance Department, Europharma, Katowice, Poland

Adv Dermatol Allergol 2022; XXXIX (5): 893–901
DOI: https://doi.org/10.5114/ada.2022.120883

Abstract

Introduction: Budesonide is one of inhaled corticosteroids with an established position in the therapy of croup, bronchial asthma and chronic obstructive pulmonary disease (COPD).

Aim: To assess factors affecting the choice of budesonide in the therapy of croup, asthma and COPD by specialists and general practitioners in daily clinical practice.

Material and methods: This multicentre, open-label, post-marketing survey was performed nation-wide with the participation of 1113 doctors and 100,980 patients treated with budesonide. The study questionnaire included questions about factors affecting the choice of budesonide and assessing the prescription pattern of the drug.

Results: The doctors frequently declared use of budesonide in monotherapy in patients with croup, and in polytherapy in asthma and COPD (with salmeterol or formoterol and with formoterol, respectively). The most important factors affecting the choice of budesonide, as declared by doctors, were safety, efficacy, good personal experience with the use of this medication and recommendations of scientific associations. Budesonide in monotherapy was prescribed in 63.7%, 49.7%, and only 13.5% of patients with croup, asthma and COPD, respectively. The most important factors which determined the choice of this drug were safety (from 78.7% to 91.0%), efficacy (from 78.9% to 90.5%) and good personal experience of doctors (from 65.6% to 84.5%).

Conclusions: Budesonide is still frequently chosen in the treatment of croup, asthma and COPD by Polish specialists and general practitioners because of its efficacy, safety and considerable experience in the application. Acquired clinical experience of physicians prevails over the issued recommendations of scientific societies regarding the use of budesonide in daily clinical practice.

Key words: croup, asthma, chronic obstructive pulmonary disease, budesonide, therapeutic preferences, efficacy, safety

Introduction

Inhaled corticosteroids (ICS) have been used in the treatment of respiratory tract diseases since 1973. The local use of corticosteroids in the respiratory tract diseases increases their efficacy and safety. The first registered ICS beclomethasone was followed by betamethasone. Budesonide and fluticasone (introduced in the 1980s), and mometasone (introduced in the 1990s) had increased anti-inflammatory action and decreased bioavailability [1].

Croup syndrome is an acute subglottic laryngitis caused by viral infection of the upper respiratory tract. Developing inflammation causes swelling of the mucous membrane of the throat, larynx and trachea. This results in a disruption of the air flow and is manifested by stridor, cough and hoarseness. In most cases, the disease has a fairly mild and self-limited course. However,
in infants it may cause severe dyspnoea and be a life-
threatening condition that requires prompt treatment.
The first line of drugs recommended in croup treatment
includes corticosteroids administered systemically (one
dose of dexamethasone orally or intramuscularly). How-
ever, it has also been shown that use of budesonide by
nebulization is effective [2–5]. The second key drug in the
treatment of croup is adrenalin by nebulization, recom-
manded in severe clinical conditions in polytherapy with
corticosteroids [6, 7].
ICS, including budesonide, are the most effective anti-
inflammatory drugs recommended in long-term control
of persistent asthma, administered once or twice daily,
depending on the severity of symptoms. ICS are also
recommended as a part of polytherapy with long-acting
β2-adrenoceptor agonists (LABA) [8].
ICS have a lower position in the management of
chronic obstructive pulmonary disease (COPD) than in
the treatment of asthma. However, a meta-analysis of
several randomized trials involving 3,976 patients with
COPD showed a reduction in the risk of exacerbation
in patients treated with high doses of ICS compared to
those receiving placebo [9]. Long-term, regular use of ICS
brings benefits to patients with severe and very severe
obstruction, who also have frequent exacerbations (at
least 2 per year) [10, 11]. However, it should be noted that
monotherapy with ICS reduces frequency of exacerbations
and improves quality of life but does not decrease
the rate of annual loss of FEV1, and general mortality [12].
Thus, ICS monotherapy is not recommended in the treat-
ment of COPD. In addition, a meta-analysis of 11 random-
ized trials has shown that polytherapy with budesonide
and formoterol or fluticasone and salmeterol significantly
decreased frequency of exacerbations and risk of death
in patients with COPD with moderate and severe bron-
chial obstruction [13].

In Poland, budesonide was approved for the treat-
ment of croup, asthma and COPD in the 1980s. How-
ever, little is known about factors affecting the choice of
budesonide in daily clinical practice.

Aim

Therefore, the aim of the multicentre, open-label,
post-marketing, observational survey was to assess fac-
tors affecting the choice of budesonide in the therapy
of croup, asthma and COPD by specialists and general
practitioners in daily clinical practice.

Material and methods

One thousand one hundred thirteen doctors (573
paediatricians, 210 general practitioners, 175 pulmonolo-
gists, 99 allergists and 56 internal medicine specialists)
participated in a nation-wide, multicentre, open-label,
post-marketing survey performed from August 2017
to December 2018. They interviewed 100,980 patients
with budesonide (54,603 diagnosed with croup,
37,408 with asthma and 8,969 with COPD). The survey
did not meet the criteria of a medical experiment and
thus did not require any Bioethics Committee approval.
The inclusion criteria for doctors were: specialty in
family medicine or internal medicine or paediatrics or
pulmonology or allergy, current license to practice, hav-
ing, in one’s practice, an appropriate number of patients
who meet the inclusion criteria for the study, completing
and signing the Application Form for the Study and send-
ing it to Europharma.
The inclusion criteria for outpatients were: diagnosis
of croup or asthma or COPD, use of budesonide in mono-
or polytherapy. The exclusion criterion was inability to
obtain answers to questions contained in the survey.
The physicians participating had a dual role in the
survey. They answered the questions regarding their
medical practice, filled out questionnaires for minimum
20 patients that fulfilled the inclusion criteria during one
visit survey resulting from a clinical need of the patient.
The first part of the questionnaire included demo-
graphic data of the doctors (specialty, work experience,
place of work) and data on their clinical practice (the fre-
cquency of using budesonide in mono- and polytherapy
in patients with croup or asthma or COPD and factors
affecting these decisions).
The second part of the questionnaire included pa-
ient demographic data (gender, age, education level,
place of residence and professional activity), clinical data
(main diagnosis, duration of asthma or COPD, clinical
symptoms of croup, severity of croup, number of asthma
and COPD exacerbations and hospitalizations during the
last 3 months, the degree of asthma and COPD control,
the need of hospitalization due to croup, recommended
treatment regimen and the occurrence of concomitant
diseases).
In addition, the patients’ opinion on effectiveness
and tolerance of budesonide were assessed on the basis
of a 4-point scale (1 – no efficacy, 2 – moderate, 3 – good,
4 – very good and 1 – difficult to accept discomfort, 2 –
acceptable discomfort, 3 – good tolerance, 4 – very good
tolerance, respectively).

Statistical analysis

Statistical analysis was performed with Statistica
12.0 software (TIBCO Software Inc., Palo Alto, CA, USA).
Values of variables were presented as percentages and
the mean values with standard deviations (SD). Separate
groups were compared using the χ² test and χ² test for
trend. The value of p < 0.05 was considered to be statisti-
cally significant.
Factors affecting the choice of budesonide in the therapy of croup, asthma and chronic obstructive pulmonary disease

Results

Doctors’ therapeutic preferences

The study group of doctors (characteristics presented in Table 1) declared the use of monotherapy with budesonide in over 50% of patients with croup. Much fewer (up to 10%) doctors declared use of polytherapy with adrenalin and budesonide. The most important factors declared by physicians as decisive for the choice of budesonide use in the treatment of croup were: efficacy (93.8%), safety (87.4%), good own experience with the use of this drug (84.1%) and convenience of the use (75.2%). These factors were followed by recommendations of scientific associations and age (65.7% and 64.6%, respectively). Meanwhile, the least importance was attributed to the cost of therapy (49.3%) and concomitant diseases (30.5%) – data not shown.

In asthma, doctors more frequently declared the use of budesonide in polytherapy than in monotherapy in over 50% of patients (36.1% vs. 15.5%). In polytherapy, doctors most frequently declared the use of budesonide with salmeterol or formoterol (56.0% and 42.0%, respectively). The most important factors declared by physicians as decisive for the choice of budesonide in the treatment of asthma were: efficacy (87.7%), safety (85.2%), good own experience with the use of this drug (75.9%) and recommendations of scientific associations (70.0%). These factors were followed by age and impact on the quality of life (QoL) (65.2% and 65.2%, respectively). Meanwhile, the least importance was attributed to the cost of therapy (47.6%), etiological factors causing the development of the disease (45.2%) and concomitant diseases (41.1%) – data not shown.

Doctors declared use budesonide in patients with COPD in polytherapy, most often with formoterol (46.3%). The most important factors declared by physicians as decisive for the choice of budesonide use in the treatment of asthma were: safety (77.5%), efficacy (73.6%), good own experience with the use of this drug (64.3%) and recommendations of scientific associations (63.6%). These factors were followed by impact on QoL and age (53.0% and 46.3%, respectively). Meanwhile, the least importance was attributed to the occurrence of concomitant diseases (42.8%), the cost of therapy (41.2%) and etiological factors causing development of the disease (38.7%) – data not shown.

Factors determining choice of budesonide in the enrolled patients

The analysis included 54,603 patients with croup, 37,408 with asthma, and 8,969 with COPD (Table 2).

The most common symptoms in patients with croup were barking cough (88.7%), hoarseness (74.1%) and inspiratory stridor (52.0%). The severity of symptoms was mild in 42.0%, moderate in 52.7% and severe in 5.3% of patients. Hospitalization was required in 4.4% of the patients (Table 3).

Table 1. Characteristics of the study group of doctors (N = 1113)

| Variable                              | N; %   |
|---------------------------------------|--------|
| Specialty:                            |        |
| Family medicine                       | 210; 18.9 |
| Internal medicine                     | 56; 5.0   |
| Paediatrics                           | 573; 51.5 |
| Allergology                           | 99; 8.9    |
| Pulmonology                           | 175; 15.7 |
| Professional experience [years]:      |        |
| 2–5                                   | 30; 2.7    |
| 6–10                                  | 51; 4.6    |
| 11–15                                 | 141; 12.7  |
| 16–20                                 | 73; 6.6    |
| > 20                                  | 818; 73.5  |
| Workplace:                            |        |
| Public hospital                       | 25; 2.2    |
| Public outpatient clinic              | 691; 62.1  |
| Private outpatient clinic             | 270; 24.3  |
| Private practice                      | 127; 11.4  |
| Workplace location:                   |        |
| Village                               | 163; 14.6  |
| City < 50 000 residents               | 466; 41.9  |
| City 50–200 000 residents             | 263; 23.6  |
| City > 200 000 residents              | 221; 19.9  |

Table 2. The percentage of patients with croup in relation to all patients taking the drug:

| Percentage of patients | N | %  |
|------------------------|---|----|
| 0%                     | 5.6 |
| 1–10%                  | 65.8|
| 11–20%                 | 22.2|
| 21–50%                 | 5.5 |
| > 50%                  | 0.9 |

The percentage of patients with asthma in relation to all patients taking the drug:

| Percentage of patients | N | %  |
|------------------------|---|----|
| 0%                     | 0  |
| 1–10%                  | 49.4 |
| 11–20%                 | 28.3|
| 21–50%                 | 11.4|
| > 50%                  | 10.9|

The percentage of patients with COPD in relation to all patients taking the drug:

| Percentage of patients | N | %  |
|------------------------|---|----|
| 0%                     | 36.9|
| 1–10%                  | 39.9|
| 11–20%                 | 18.1|
| 21–50%                 | 4.2 |
| > 50%                  | 0.8 |
Patients with asthma were characterized by varied duration of the disease, assessed as controlled in 68.0%, partially controlled in 27.5% and uncontrolled in 4.4% of the study group. In the last 3 months, exacerbations of the disease were reported in 39.3% of patients (in 80.1% one, 17.2% two and 2.7% more than two), and hospitalizations due to exacerbations in the last 3 months in 9.3% of patients with asthma. Concomitant diseases were reported in 39.4% of patients, most often other allergic diseases (Table 3).

Patients with COPD were characterized by varied duration of the disease, assessed as category A in 23.1%, B in 47.2%, C in 25.3% and D in 4.5% of patients. During the last 3 months, exacerbations of the disease and related hospitalizations were reported in 37.9% (in 66.0% one, 24.2% two and 9.8% more than two) and 11.2% of patients, respectively. Concomitant diseases, mostly cardiovascular and metabolic, occurred in 71.0% of patients (Table 3).

Budesonide was used in monotherapy in 63.7% and in polytherapy in 36.3% of patients with croup. The most important factors determining the use of budesonide in the treatment of croup were: safety, efficacy, own experience of the doctor with the use of this drug, convenience of use, age of patients and recommendation of scientific associations (Tables 3 and 4).

Budesonide was used in monotherapy in 49.7% and in polytherapy (most often with formoterol and salmeterol) in 50.3% of patients with asthma. In monotherapy, it was commonly used in patients with controlled asthma. The most important factors determining the use of budesonide in treatment of asthma were: safety, efficacy and own experience of the doctor with the use of this drug (Table 3 and 4).

Budesonide was used in monotherapy in 13.5% and in polytherapy (most often with formoterol and salmeterol) in 86.5% of patients with COPD. Budesonide in monotherapy was commonly used in patients with COPD meeting category A. The most important factors determining the use of budesonide in treatment of croup were: efficacy, safety and considerable experience of the doctor with the use of this drug (Tables 3 and 4).

The efficacy and tolerance of pharmacotherapy including budesonide

Efficacy and tolerance of the therapy with budesonide are presented in Figures 1 and 2. In all cases they were

Table 2. Characteristics of study groups of patients treated with budesonide

| Variable                  | Croup (N = 100,980) | Asthma (N = 37,408) | COPD (N = 8,696) | P-value |
|---------------------------|---------------------|--------------------|-----------------|---------|
| Age [years]               | 7 ±9                | 21 ±19             | 59 ±16          | < 0.001 |
| Gender, n; %:             |                     |                    |                 |         |
| Women                     | 28,585; 52.4        | 20,891; 55.8       | 3,591; 40.0     | < 0.001 |
| Men                       | 26,018; 47.6        | 16,517; 44.2       | 5,378; 60.0     | < 0.001 |
| Education levels, n; %:   |                     |                    |                 |         |
| Not applicable            | 49,751; 91.1        | 20,669; 55.3       | 282; 3.1        |         |
| Primary                   | 1,604; 2.9          | 2,699; 7.2         | 1,077; 12.0     | < 0.001 |
| Vocational                | 604; 1.1            | 2,927; 7.8         | 3,648; 40.7     |         |
| Secondary                 | 1,775; 3.3          | 7,015; 18.8        | 2,656; 29.6     |         |
| Higher                    | 869; 1.6            | 4,098; 11.0        | 1,306; 14.6     |         |
| Place of residence, n; %: |                     |                    |                 |         |
| Village                   | 18,751; 34.3        | 9,792; 26.2        | 3,438; 38.3     | < 0.001 |
| City < 50 000 residents   | 15,174; 27.8        | 11,047; 29.5       | 3,442; 38.4     |         |
| City 50–200 000 residents | 13,758; 25.2        | 9,063; 24.2        | 1,179; 13.1     |         |
| City > 200 000 residents  | 6,920; 12.7         | 7,506; 20.1        | 910; 10.1       |         |
| Professional activity, n; %: |                  |                    |                 |         |
| Intellectual work         | 1,417; 2.6          | 5,869; 15.7        | 1,392; 15.5     |         |
| Physical work             | 931; 1.7            | 4,744; 12.7        | 2,097; 23.4     |         |
| Not working               | 970; 1.8            | 1,828; 4.9         | 908; 10.1       |         |
| Sickness pension          | 50; 0.1             | 598; 1.6           | 936; 10.4       |         |
| Pension                   | 124; 0.2            | 1,016; 2.7         | 3,241; 36.1     |         |
| Not applicable            | 51,111; 93.6        | 23,353; 62.4       | 395; 4.4        |         |
Factors affecting the choice of budesonide in the therapy of croup, asthma and chronic obstructive pulmonary disease

### Table 3. Clinical characteristics of the study groups

| Variable                                      | Croup (N = 100,980) | Asthma (N = 37,408) | COPD (N = 8,696) | P-value |
|-----------------------------------------------|----------------------|---------------------|------------------|---------|
| Duration of the disease, n; %:                |                      |                     |                  |         |
| > 5 years                                     | 13,807; 36.9         | 4,550; 51.7         |                  | < 0.001 |
| 4–5 years                                     | 5,966; 15.9          | 1,846; 21.0         |                  |         |
| 2–3 years                                     | 7,363; 19.7          | 1,293; 14.7         |                  |         |
| 12–23 months                                  | 3,888; 10.4          | 258; 2.9            |                  |         |
| 7–11 months                                   | 2,384; 6.4           | 198; 2.2            |                  |         |
| 3–6 months                                    | 2,463; 6.6           | 515; 5.8            |                  |         |
| < 3 months                                    | 1,537; 4.1           | 149; 1.7            |                  |         |
| Clinical symptoms, n; %:                      |                      |                     |                  |         |
| Fever                                         | 26,458; 48.5         |                     |                  |         |
| Hoarseness                                    | 40,461; 74.1         |                     |                  |         |
| Inhalation stridor                             | 28,400; 52.0         |                     |                  |         |
| Barking cough                                 | 48,435; 88.7         |                     |                  |         |
| Wheezing                                      | 14,443; 26.5         |                     |                  |         |
| Dyspnoea                                      | 11,677; 21.4         |                     |                  |         |
| Faster breathing                               | 8,772; 16.1          |                     |                  |         |
| Visible movement of the wings of the nose     | 2,238; 4.1           |                     |                  |         |
| Visible intercostal retraction                | 2,021; 3.7           |                     |                  |         |
| Patients requiring hospitalization, n; %      | 2,388; 4.4           |                     |                  |         |
| Severity of the disease, n; %:                |                      |                     |                  |         |
| Mild                                          | 22,942; 42.0         |                     |                  |         |
| Moderate                                      | 28,788; 52.7         |                     |                  |         |
| Severe                                        | 2,873; 5.3           |                     |                  |         |
| GINA criteria, n; %:                          |                      |                     |                  |         |
| Controlled asthma                             | 25,437; 68.0         |                     |                  |         |
| Partially controlled asthma                   | 10,287; 27.5         |                     |                  |         |
| Uncontrolled asthma                           | 1,684; 4.5           |                     |                  |         |
| GOLD criteria, n; %:                          |                      |                     |                  |         |
| Category A                                    | 2,068; 23.1          |                     |                  |         |
| Category B                                    | 4,229; 47.2          |                     |                  |         |
| Category C                                    | 2,269; 25.3          |                     |                  |         |
| Category D                                    | 403; 4.5             |                     |                  |         |
| Use of budesonide, n; %:                      |                      |                     |                  |         |
| Monotherapy                                   | 34,779; 63.7         | 18,578; 49.7        | 1,211; 13.5      |         |
| Polytherapy                                   | 19,824; 36.3         | 18,830; 50.3        | 7,758; 86.5      |         |
| Drugs used in polytherapy with budesonide (%) |                      |                     |                  |         |
| Formoterol                                    | 25.1                 | 40.8                |                  |         |
| Salmeterol                                    | 23.3                 | 35.0                |                  |         |
| Indacaterol                                   | 1.9                  | 10.7                |                  |         |
| Exacerbation of the disease during the last 3 months (%) |            |                     |                  |         |
| Once                                          | 55.3                 | 66.0                |                  |         |
| Twice                                         | 33.2                 | 24.2                |                  |         |
assessed as very good and good by more than 95% of patients.

Discussion

The presented study is the first large survey that assessed factors affecting doctors’ therapeutic preferences for the use of budesonide in patients with croup or asthma or COPD among specialists and general practitioners in daily clinical practice, performed in Poland. It should also be noted that so far such a study has not been performed in other countries.

Our study has shown that in patients with croup, budesonide is more frequently used in mono- than in polytherapy and the drug choice is related to its safety, efficacy, and considerable experience with the use of the drug. The results obtained in the observed group are in accordance with doctors’ declarations contained in the first part of survey. In both cases, the low position of recommendations of scientific associations may surprise. However, it should be noted that prescription profiles—the result of therapeutic decisions are in the majority in line with them [14]. Meanwhile, the small significance attributed by doctors to the cost of therapy is understandable in view of the nature of this acute illness, constituting a significant threat to the life and health of children, as well as partial reimbursement of these drugs by the Polish National Health Fund (NFZ). In addition, according to clinical trials [15], our study showed that budesonide is effective in the treatment of croup and very well tolerated. The subjective assessment of efficacy is supported by observation that less than 5% of patients with croup required hospitalization.

Doctors more frequently declared use of budesonide in the treatment of asthma in polytherapy with salmeterol or formoterol than in monotherapy. Meanwhile, the analysis of prescription profiles in the observed group showed that budesonide is used in mono- and polytherapy with formoterol or salmeterol with similar frequency. Budesonide in monotherapy was used mainly in well-controlled asthma. It should be noted that use of budesonide in monotherapy is not compatible with GINA recommendations [8] although 70% of doctors declared and 62% indicated in patient survey that recommendations of scientific associations are among the most important factors affecting the choice of budesonide in the treatment of asthma. However, it should be noted that in the observed group the most important factors determining the use of budesonide in treatment of asthma were: safety, efficacy and doctors’ considerable experience with the use of this drug. The doctors paid little attention to the costs of this chronic therapy, which is most probably associated with high refunding of this group of drugs by NFZ. In addition, according to clinical trials [16], our study showed that budesonide is effective and very well tolerated in the treatment of asthma. The subjective assessment of efficacy is supported by the observation that less than 10% of patients required hospitalization due to exacerbation of asthma during the last 3 months.

In treatment of COPD, doctors declared mostly the use of budesonide in polytherapy in up to 50% of patients. Despite these declarations that are in accordance with present recommendations [8], in the observed group budesonide was used in monotherapy only in 13.5% and in polytherapy with LABA (usually with formoterol or salmeterol) in 86.5%. Budesonide in combination with formoterol was used frequently and it was consistent with

---

### Table 3. Cont.

| Variable                          | Croup (N = 100,980) | Asthma (N = 37,408) | COPD (N = 8,696) | P-value |
|----------------------------------|---------------------|---------------------|------------------|---------|
| Hospitalization during the last 3 months (%) | 11.5                | 9.8                 |                  |         |
| Once                             | 9.3                 | 11.2                |                  |         |
| Twice                            | 80.1                | 86.4                |                  |         |
| More than twice                  | 2.7                 | 5.0                 |                  |         |
| Concomitant diseases (%)         | 39.4                | 71.0                |                  |         |
| Obesity                          | 8.0                 | 21.5                |                  |         |
| Type 1 diabetes                  | 0.8                 | 2.0                 |                  |         |
| Type 2 diabetes                  | 2.3                 | 19.2                |                  |         |
| Hypertension                     | 9.5                 | 60.4                |                  |         |
| Dyslipidaemia                    | 3.2                 | 31.2                |                  |         |
| Coronary heart disease           | 2.2                 | 21.4                |                  |         |
| Other allergic diseases           | 20.7                | 3.0                 |                  |         |
| Other chronic diseases           | 4.3                 | 9.2                 |                  |         |
### Table 4. Factors influencing the use of budesonide

| Variable                                                                 | Croup                  | Asthma                  | COPD       | P-value |
|-------------------------------------------------------------------------|------------------------|-------------------------|------------|---------|
|                                                                         | (N = 100,980)          | (N = 37,408)            | (N = 8,696)|         |
| Patients’ age (%)                                                        |                        |                         |            | < 0.001 |
| Insignificant                                                           | 9.0                    | 17.9                    | 23.5       |         |
| Important                                                               | 18.5                   | 26.5                    | 33.3       |         |
| Very important                                                          | 72.5                   | 55.6                    | 43.3       |         |
| The etiological factor causing the development of the disease (%)       |                        |                         |            | < 0.001 |
| Insignificant                                                           | –                      | 20.6                    | 21.5       |         |
| Important                                                               | –                      | 32.3                    | 39.9       |         |
| Very important                                                          | –                      | 47.1                    | 38.6       |         |
| Convenience of use (%)                                                  |                        |                         |            |         |
| Insignificant                                                           | 4.1                    | –                       | –          |         |
| Important                                                               | 17.4                   | –                       | –          |         |
| Very important                                                          | 78.5                   | –                       | –          |         |
| Comorbidities (%)                                                       |                        |                         |            | < 0.001 |
| Insignificant                                                           | 38.8                   | 32.4                    | 14.2       |         |
| Important                                                               | 19.8                   | 29.6                    | 38.3       |         |
| Very important                                                          | 41.3                   | 37.9                    | 47.5       |         |
| Efficacy (%)                                                            |                        |                         |            |         |
| Insignificant                                                           | 0.2                    | 0.3                     | 0.0        |         |
| Important                                                               | 9.3                    | 15.6                    | 21.3       |         |
| Very important                                                          | 90.5                   | 84.1                    | 78.7       |         |
| Safety (%)                                                              |                        |                         |            |         |
| Insignificant                                                           | 0.1                    | 0.1                     | 0          |         |
| Important                                                               | 8.9                    | 15.1                    | 21.1       |         |
| Very important                                                          | 91.0                   | 84.9                    | 78.9       |         |
| One’s own good experience with the use of the drug (%)                  |                        |                         |            |         |
| Insignificant                                                           | 0.6                    | 0.6                     | 1.1        |         |
| Important                                                               | 14.9                   | 23.5                    | 33.3       |         |
| Very important                                                          | 84.5                   | 75.9                    | 65.6       |         |
| Cost of therapy (%)                                                     |                        |                         |            |         |
| Insignificant                                                           | 16.6                   | 16.5                    | 11.7       |         |
| Important                                                               | 29.0                   | 30.8                    | 37.5       |         |
| Very important                                                          | 54.4                   | 52.6                    | 50.9       |         |
| Recommendation of the Scientific Association (%)                         |                        |                         |            | < 0.001 |
| Insignificant                                                           | 3.7                    | 3.0                     | 1.5        |         |
| Important                                                               | 26.2                   | 34.8                    | 38.9       |         |
| Very important                                                          | 70.1                   | 62.2                    | 59.6       |         |
| Effect on patients’ quality of life (%)                                 |                        |                         |            | < 0.001 |
| Insignificant                                                           | –                      | 7.8                     | 9.7        |         |
| Important                                                               | –                      | 28.2                    | 31.3       |         |
| Very important                                                          | –                      | 64.0                    | 59.0       |         |
doctors’ declarations. Doctors declared that the most important factors affecting the choice of budesonide in the treatment of COPD are safety, efficacy and their own considerable experience with the use of this drug. The same factors determined the choice of budesonide in the study group. Also in the case of COPD, little importance was paid to the costs of this chronic therapy, which is most likely associated with high refunding of this group of drugs by NFZ. In addition, according to meta-analysis [17], our study showed that budesonide in polytherapy with LABA is effective in COPD treatment and very well tolerated. The subjective assessment of efficacy is supported by the observation that 11.2% of patients required hospitalization due to asthma exacerbation during the last 3 months.

In summary, our multicentre, open-label, post-marketing survey showed that budesonide is willingly used in treatment of croup, asthma and COPD by Polish general practitioners and specialists and its use, excluding asthma, is in accordance with recommendations.

Conclusions

Budesonide is still frequently chosen in the treatment of croup, asthma and COPD by Polish specialists and general practitioners because of its efficacy, safety and considerable experience in the application. Acquired clinical experience of physicians prevails over the issued recommendations of scientific societies regarding the use of budesonide in daily clinical practice.

Acknowledgments

The study was carried out as a research project supported by a scientific grant of Adamed Pharma organized by Europharma M. Rachtan Sp. z o.o. Poland.

Conflict of interest

Magdalena Olszanecka – Glinianowicz received honorarium for study concept from Europharma. Jerzy Chudek received honorarium for co-edition from Europharma. Anna Urcus – employed by the funding organization. Agnieszka Almgren-Rachtan – received honorarium for co-edition from Europharma.

References

1. Price J. The role of inhaled corticosteroids in children with asthma. Arch Dis Child 2000; 82 Suppl 2: I10-I4.
2. Fifoot AA, Ting JY. Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized, double-blinded clinical trial. Emerg Med Australas 2007; 19: 51-8.
3. Amir L, Hubermann H, Halevi A, et al. Oral betamethasone versus intramuscular dexamethasone for the treatment of mild to moderate viral croup: a prospective, randomized trial. Pediatr Emerg Care 2006; 22: 541-4.
4. Russell KF, Liang Y, O’Gorman K, et al. Glucocorticoids for croup. Cochrane Database Syst Rev 2011; 1: CD001955.
5. Richier KK, Ledwith CA. Outpatient treatment of moderate croup with dexamethasone: intramuscular versus oral dosing. Pediatrics 2000; 106: 1344-8.
6. Bjornson C, Russell KF, Vandermeer B, et al. Nebulized epinephrine for croup in children. Cochrane Database Syst Rev 2011; 2: CD006619.
7. Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. Am J Dis Childr 1978; 132: 484-7.
8. Global Strategy for Asthma Management and Prevention (GINA) Revised 2014. Available from: http://www.ginasthma.com/
9. Zhai Y, Zhang H, Sun T, et al. Comparative efficacies of inhaled corticosteroids and systemic corticosteroids in treatment of chronic obstructive pulmonary disease exacerbations: a systematic review and meta-analysis. J Aerosol Med Pulm Drug Deliv 2017; 30: 289-98.
10. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
11. Calverley PM, Kuna P, Monsó E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med 2010; 104: 1858-68.
12. Dahl R, Chung KF, Buhl R, et al. INVOLVE (Indacaterol: Value In COPD: Long Term Validation of Efficacy and Safety Study Investigators. Efficacy of a new once-daily LABA, indacaterol versus twice-daily LABA formoterol in COPD. Thorax 2010; 65: 473-9.
13. Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003; 327: 643-9.
14. Gates A, Gates M, Vandermeer B, et al. Glucocorticoids for croup in children. Cochrane Database Syst Rev 2018; 8: CD001955.
15. Cetinkaya F, Tufekci BS, Kutluk G. A comparison of nebulized budesonide, and intramuscular, and oral dexamethasone for treatment of croup. Int J Pediatr Otorhinolaryngol 2004; 68: 453-6.
16. Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 485-518.
17. Tang B, Wang J, Luo LL, et al. Comparative efficacy of budesonide/formoterol with budesonide, formoterol or placebo for stable chronic obstructive pulmonary disease: a meta-analysis. Med Sci Monit 2019; 25: 1155-63.